Kailera Therapeutics, Inc. (KLRA)
NASDAQ: KLRA · Real-Time Price · USD
23.15
-0.36 (-1.53%)
Apr 28, 2026, 2:34 PM EDT - Market open
Kailera Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
| Selling, General & Admin | 49.23 | 14.06 |
| Research & Development | 109.11 | 10.46 |
| Operating Expenses | 158.34 | 24.52 |
| Operating Income | -158.34 | -24.52 |
| Interest & Investment Income | 11.05 | 3.76 |
| Other Non Operating Income (Expenses) | -1.66 | 12.29 |
| EBT Excluding Unusual Items | -148.96 | -8.46 |
| Pretax Income | -148.96 | -329.57 |
| Net Income | -148.96 | -329.57 |
| Net Income to Common | -148.96 | -329.57 |
| Shares Outstanding (Basic) | 0 | - |
| Shares Outstanding (Diluted) | 0 | - |
| EPS (Basic) | -7819.98 | - |
| EPS (Diluted) | -7819.98 | - |
| Free Cash Flow | -122.3 | -185.35 |
| Free Cash Flow Per Share | -6420.52 | - |
| EBITDA | -158.03 | -24.44 |
| D&A For EBITDA | 0.31 | 0.08 |
| EBIT | -158.34 | -24.52 |
Source: S&P Capital IQ. Standard template.
Financial Sources.